Health Condition 1: L910- Hypertrophic scar
Conditions
Interventions
Intervention1: Fractional CO2 laser assisted delivery of 8 percent pirfenidone gel combined with intralesional triamcinolone acetonide.: Fractional CO2 laser treatment will be performed in DEEP FX mod
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: Patients of either gender aged 15 60 years with clinically diagnosed keloids measuring 2 10 cm in largest diameter, who are treatment-na ve and have stable lesions for at least 6 months, located on the trunk, extremities, or neck.
Exclusion criteria
Exclusion criteria: 1.Patients with infected keloids or coexisting inflammatory systemic skin diseases 2.Unrealistic expectations or psychiatric illnesses 3.Pre existing bleeding disorders 4.Lactating/pregnant patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare keloid volume change from baseline to end of treatment between CO2 laser-assisted topical pirfenidone gel with ILTAC and CO2 laser with ILTAC alone using Antera 3D volumetric measurementsTimepoint: After week 24 | — |
Secondary
| Measure | Time frame |
|---|---|
| changes in scar texture parameters (roughness and height), hemoglobin and melanin indices measured by Antera 3D, and recurrence monitoring through volumetric and chromophore analysis at follow-up. Additional assessments include clinician-rated Vancouver Scar Scale and POSAS observer scores, patient-reported POSAS, visual analogue scales for itch and pain, and satisfaction Likert scores. Safety endpoints include incidence and severity of corticosteroid-related effects (atrophy, telangiectasia, hypopigmentation, pain) and local pirfenidone reactions (erythema, burning, pruritus), documented throughout treatment and follow-upTimepoint: After week 24 | — |
Countries
India
Contacts
Public ContactDr Madura C
CUTIS Academy of Cutaneous Sciences
Outcome results
None listed